Osteopore®

Investor Presentation

MARCH 2025

ASX: OSX

Disclaimer

This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company.
No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

Introduction

Osteopore Ltd. is a global medical technology company commercialising products that enable tissue regeneration across multiple therapeutic areas.

Through our cutting-edge 3D printing technology and bioresorbable materials, Osteopore manufactures micro-structured scaffolds for tissue regeneration.

Osteopore's patented scaffolds are made using a proprietary manufacturing technique that comprises a dissolvable polymer.

Our world-class scaffolds support natural tissue development, significantly reducing post-surgery complications and improving patient quality of life.

Osteopore®

Vision
Be the most valuable regenerative medical technology company in the world

Mission
Harness our superior technology to become the standard of care globally for natural tissue regeneration

Goal
Improve clinical outcomes and patient quality of life

Our business segments

Craniofacial

USD $1.1b global market (2022)

8.3% CAGR (2023-2032)

15yrs+ clinical use

Global footprint

1 Allied Market Research, 'Craniofacial Implants Market Size' (2022)

Aesthetic (Rhinoplasty)

USD $5.88b global market (2022)

7.3% CAGR (2023-2030)

8yrs+ clinical use

Global footprint

2 Grand View Research, 'Rhinoplasty Market Size' (2023)

Orthopaedic

USD $48b global market (2022)

5.3% CAGR (2023-2032)

6yrs+ clinical use

Global footprint

3 Fortune Business Insights, 'Orthopaedic Implants Market Size' (2024)

Dental & OMF

USD $4.43b global market (2023)

6.9% CAGR (2023-2032)

3yrs+ clinical use

Global footprint

4 Fortune Business Insights, 'Dental Implants Market Size' (2024)

Investment highlights

1#
Revenue Generating

Post-sales revenue-generating regenerative medicine company.

2#
Pipeline Investment

Committed to product & sector expansion and future product line development.

3#
Market Potential

High market valuation with significant growth opportunities. The regenerative medicine market is projected to reach A$120b by 2035.

4#
Value-based Care

Leverage strong connections with technology sectors to deliver economic growth and superior patient outcomes.

Regenerative medicine

Exciting market opportunity with growth potential

High market valuation	Links to multiple technology sectors	Value-based care
• In 2023, the global **regenerative medicine market was worth USD $34.56b** [1] • The regenerative medicine market is expected to **grow to USD $398.77b by 2032** [1]	• Links the multi-billion-dollar **medtech, biotech and pharmaceutical sectors** • **Economic growth and better patient outcomes** through industry collaboration	• With the power to reduce drugs, devices and surgeries, the **cost of care can be significantly reduced** • Tackling global inefficiencies in healthcare systems could **unlock ~2 trillion annually** by 2025 [2]

1 Regenerative Medicine Market Size, Share & Industry Analysis, Fortune Business Insights

2 McKinsey Global Institute Report, 2017, McKinsey

Breakthrough technology, regenerative products

Unique technology

- Breakthrough technology that leverages **3D printing to enable bone regeneration**
- **Bioscaffold serves as a template** for bone to grow and bridge bone gaps
- 3D printed bioresorbable **implant dissolves within 18 to 24 months**
- Concurrently, the bioscaffold is **replaced with the patient's bone**

Value proposition

- **World's first biomimetic bioscaffold** that dissolves naturally over time as bone regenerates
- Can be **manufactured at scale**
- **Proven, high-quality alternative** that augments clinical outcomes
- Efficient cost structure to **extract value** while **ensuring reasonable access** to high quality implants

Multiple applications

Application areas:

- Craniofacial
- Aesthetic (rhinoplasty)
- Orthopaedic
- Dental

Off-the-shelf and Patient-Specific Implants available*

- Products designed to cater to different surgical needs
- Off-the-shelf implants cater to >90% of cases
- Patient Specific Implant enables reach to complex cases

* Availability varies according to country / region

Unlocking USD $1.9b in market potential



** Colombia and Panama*

Leveraging 3D printing to create scaffolds that guide tissue regeneration

Regenerative implants

Osteopore is **pushing the boundaries of 3D printing** to develop and commercialise biomimetic microstructure that **enables natural tissue regeneration**.

Biomimetic microstructure



Cell proliferation



Tissue regeneration



Dramatically improving patient Quality of Life

Creating a step-change in patient Quality of Life after significant bone loss due to surgery

Bone defect

150mm bone loss due to tumor resection

Pre-surgery

Early PSI mineralisation

Initial osseous in-growth

20kg partial weight-bearing

3 weeks

4 months

Early ambulation

120kg patient

6 months

Bone remodelling

Complete bone bridging from proximal to distal (150mm)

10 months

Function restored

Back to work

OSTEOPORE.COM

Our applications

Patient-centred design

- Aesthetics (Rhinoplasty)
- Craniofacial
- Orthopaedic
- Dental/OMF

Aesthetics (Rhinoplasty)

Proven solutions in septal extension grafting

Neurosurgery

Proven solutions in burr holes, craniotomy, skull base, cranial vault remodelling and cranioplasty

Dental

Proven solutions and developing applications in alveolar ridge preservation, guided bone regeneration and mandibular reconstruction

Orbital Surgery

Proven solutions in orbital floor reconstruction

Orthopaedic Surgery Upper Body

Developing applications in rotator cuff repair, clavicle non-union, sternum augmentation and distal radius bone reconstruction

Orthopaedic Surgery Lower Body

Developing applications in mid-shaft bone reconstruction, high tibial osteotomy and lower extremity bone filler applications

Craniofacial

Core business

Craniotomy

Product Example

Enables the complete restoration of patients' skull contours in post-craniotomy procedures



Orbital floor reconstruction

Product Example

Delivers structural support and consistent bone regeneration for orbital floor fractures

Now

- **51K+** cumulative implants
- **15+** years of clinical experience
- Footprint in **25+** countries including the USA
- **150%** adoption growth in 2022
- CAGR of **8.3%** by 2032[1]

Objectives

- **Strengthen** commercial distribution network & Key Opinion Leader network
- **Invest** in Medical Education
- **Develop** new applications with existing products, such as **skull base surgery**
- Progress towards **Chinese market entry**

1 Allied Market Research, 'Craniofacial Implants Market Size' (2022)

Aesthetic (Rhinoplasty)

Core business

Nasal tip plasty

Product Example

Adds projection to the nasal tip for a natural and aesthetically pleasing augmentation



Septal extension grafting

Product Example

Provides structural support to achieve long-term and aesthetically pleasing nose augmentation outcomes

Now

- **61K+** cumulative implants
- Functional and **cosmetic rhinoplasty**
- **8+** years of clinical experience
- Footprint in **10+** countries including Korea
- CAGR of **7.3%** by 2030[2]

Objectives

- **Expand** into new markets in APAC and ASEAN
- **Invest** in product handling workshops
- **Develop** new applications with existing products

2 Grand View Research, 'Rhinoplasty Market Size' (2023)

Orthopaedic

Core business

Now

- **135** cumulative implants
- **6+** years of clinical experience
- Footprint in **5+** countries
- CAGR of **5.3%** by 2032[3]

High Tibial Osteotomy

Product Example

Wedge support implants in HTO regenerative knee preservation

Objectives

- **Commercialise** in ASEAN and APAC with partners that have established distribution channels and customer relationship
- **Invest** in Medical Education to grow product awareness
- **Identify** and offer solutions for limb-salvage and no-option patients

Segmental Bone Reconstruction

Product Example

Biological bone scaffold to support regeneration

3 Fortune Business Insights, 'Orthopaedic Implants Market Size' (2024)

Dental & OMF

Core business

Socket preservation

Product Example

Regenerate bone in socket to facilitate dental implant placement



Guided bone regeneration

Product Example

Semi-flexible membrane to maintain alveolar width and height

Now

- **580+** cumulative implants
- Footprint in **3+** countries including Indonesia
- **Pipeline development** to accelerate regeneration
- CAGR of **6.9%** by 2030[4]

Objectives

- **Drive** adoption in ASEAN and APAC
- **Invest** in Medical Education and workshops to grow product awareness and surgical handling
- **Develop** next-generation technology to accelerate bone regeneration

4 Fortune Business Insights, 'Dental Implants Market Size' (2024)

World-first surgeries, life-changing outcomes

Cranial remodelling

The cranial remodelling of a child with craniosynostosis – a premature fusion of the skull.

The patient made an incredible recovery, enrolling at preschool in just three months [1].

Facial and orbital floor reconstruction

The use of 3D bioabsorbable implants to replace a permanent implant.

The patient felt no more pain in her cheekbone and regained her confidence [2].

Skull reconstruction

Skull reconstructed after a craniotomy – bone removed from the skull.

The patient recovered well with new bone growth in only 6 months [3].

Half ribcage reconstruction

Half ribcage using Singapore's first 3D-printed biocompatible and bioabsorbable implant.

Improved the patient's self-esteem and quality of life [4].

Heel bone reconstruction

Heel bone reconstruction to save the leg from amputation.

Singaporean auxiliary policeman with a shattered leg overcame his fear and rose to his feet [5].

Skull reconstruction

Front skull reconstruction to restore the 'normal' anatomy of the skull.

Improved the patient's appearance and preserved her eye [6].

[1] https://singaporemotherhood.com/craniosynostosis-shaped-her-little-girls-head/

[2] https://thehomeground.asia/destinations/singapore/3d-implant-gives-young-mother-fresh-start-after-surviving-hit-and-run-10-years-ago/

[3] https://www.straitstimes.com/singapore/3d-printed-regenerative-bone-implants-give-patient-new-lease-of-life-after-head-injury

[4] https://www.sgh.com.sg/news/patient-care/sgh-pioneers-chest-deformity-treatment-with-3d-printed-implant

[5] UTUSAN MALAYSIA, 20 Feb 2023

[6] https://www.straitstimes.com/singapore/11-hour-surgery-to-give-girl-with-birth-defect-a-new-face

World-first surgeries, life-changing outcomes

Segmental bone defect

Largest-ever construction of a segmental bone defect [1]

- Reconstruction of a 36cm tibia
- Incredible recovery, returning to daily routine after 2yrs


Gold Coast man receives 3D-printed world-first surgery

Tony Moore

September 8, 2017 – 2.57pm

Surgeons at Brisbane's Princess Alexandra Hospital have performed world-first surgery and transplanted a 3D printed shinbone into the leg of a man who faced losing his leg.

Two weeks ago, the 3D printed tibia was transplanted into the Reuben Lichter's right leg.

Post-cancer bone reconstruction

Post-cancer reconstruction of a 15cm tibia [2]

- Reconstruction saved leg from being amputated
- The patient's amazing recovery featured in *Australian Women's Weekly*

Half mandible reconstruction

World's first half-mandible reconstruction using a synthetic implant [3]

- Bone growth confirmed 1 year after surgery
- Patient reintegrated into society and daily routine

3D printed skull implant

World's first 3D-printed implant to replace missing pieces of skull [4]

- Reconstruction saved the patient's life
- Enabled patient to return to swimming



[1] https://www.abc.net.au/news/2019-10-18/3d-printed-tibia-patient-walking-unaided-2-years-on-from-surgery/11617878

[2] The Australian Women's Weekly, 2023

[3] https://www.9news.com.au/national/man-first-to-receive-printed-jaw-in-queensland/1185bfed-2ab1-416c-8e29-112f53d9c03e?OCID=Social-9newsB

[4] https://www.brisbanetimes.com.au/national/queensland/brisbane-man-regrows-skull-in-world-first-procedure-20200602-p54yrn.html

Our global footprint – current and future



Delivering sustained commercial growth

- Consistent growth in annual revenue
- **Record revenue in CY 2024: AUD $2.8M**
- High gross margin business >80% (CY 24) [1]



[1] Appendix 4E

OSTEOPORE.COM

Our business model and growth strategy

Continuously review and strengthen distribution network to accelerate revenue growth

Obtain additional regulatory approval to expand sales (China, Japan) and **register new products** to access new markets and revenue (orthopaedic, dental)

Invest in both organic growth and inorganic growth opportunities, such as **mergers and acquisitions (M&A)**

Undertake market development and business development activities to further **enhance revenue in key markets**

Direct-to-customer**- Unlock revenue synergies** by selling products direct-to-customer to **boost margins**, scale **direct sales**, and increase per-product revenue, driving **cashflow positivity.**

Value-creation**- Invest in technologies** and intangible assets to **boost competitive advantage** and ensure operational freedom, enhancing our market position via strategic collaboration.



Our global strategy

Partnership
Sourcing and matching partners to our product segments to **commercialise and distribute our products globally**

Regulatory approval
Conducting pre-market testing and clinical trials to **secure market approval in APAC, ASEAN, Greater China as well as EMEA and LATAM**

Market entry
Identifying grants and other capital streams to **support market entry into lucrative global markets including Brazil and China**

R&D
Pursuing additional **research and development opportunities** in APAC, Greater China and LATAM

Blue-sky outcomes

Commercialising next-gen biologics and additives

Osteopore is collaborating with research organisations to develop and commercialise biologics and additives that accelerate bone and tissue regeneration.

ASX announcement: 'Osteopore secures A$19m clinical-industrial partnership', 13 Dec 2021

ASX announcement: 'Chile Government and University co-fund Osteopore research', 28 Sep 2022

ASX announcement: 'Osteopore to Commercialise Innovative Bone Regeneration Technology', 14 Apr 2023

Strengthening rotator cuff augmentation

Osteopore is collaborating with Livingstone Health to treat damaged rotator cuffs with implant scaffolds.

ASX announcement: 'Collaboration With Healthcare Group To Develop New Products', 20 Jun 2022

Investing in future regenerative and prevention technologies

Osteopore initiates the development of future regenerative and preventive technologies such as stem cells for scaffold-based cell therapy

ASX announcement: 'Osteopore partners with CytoMed to advance MSC-powered regeneration ', 17 Oct 2024

ASX announcement: 'Osteopore to join forces with renowned scientists……' 4 Nov 2024

Our leaders

Mark Leong
Executive Chairman
ACCA, ISCA, SID

Lim Yujing
Executive Director, CEO & CTO
PhD Bioengineering (Singapore)

Prof. Teoh Swee Hin
Non-Executive Director
B Eng. (1st Hons);
PhD Materials Engineering (Singapore)

Daniel Ow
Non-Executive Director
B.Com; CPA (Australia)

Hon. Michael Keenan
Non-Executive Director
B. Arts; B. Arts (Hon); M. Phil. (UK)

Voon Shu Ning
Financial Controller
CPA (Australia)

Ammar Hassanbhai
Senior Manager, Quality Assurance
(Singapore)

Our advisors

Neurosurgery

Dr. Rondhir Jithoo MD
Neurosurgeon
Alfred Hospital
(Au.)

A/Prof. Yeo Tseng Tsai
Neurosurgeon
National University Hospital
(Sg.)

Orthopaedic

Clinical Asst. Prof. Hamid Razak
Consultant Orthopaedic Surgeon
Sengkang General Hospital
(Sg.)

Dr. James Tan MD
Orthopaedic Surgeon
Quantum Orthopaedics
(Sg.)

A/Prof. Andrew Chin Yuan Hui
Senior Consultant Hand and Reconstruction Surgeon
Singapore General Hospital
(Sg.)

Dr. Henry Soeharno
Orthopaedic Surgeon
Singapore General Hospital
(Sg.)

R&D

Tan Kim Cheng
Senior Lecturer
Temasek Polytechnic
(Sg.)

Dental/Oral Maxillofacial

Dr. Samintharaj Kumar MD
CEO & Founder
Nuffield Dental Group
(Sg.)

Dr. GK Ananda MD
Oral Maxillofacial Surgeon
Gleneagles Hospital
(My.)

Craniofacial

Dr. Michael Wagels MD
Plastic Reconstructive Surgeon
Princess Alexandra Hospital
(Au.)

A/Prof. Lim Thiam Chye
Plastic Reconstruction Surgeon
National University Hospital
(Sg.)

A/Prof. Chew Khong Yik
Plastic Reconstruction Surgeon
Singapore General Hospital
(Sg.)

Radiology

Dr. Tan Bang Wei (Mark)
Head & Neck Radiology;
Clinical 3D Printing
Singapore General Hospital
(Sg.)

Why Osteopore?

De-risked profile

- Globally **validated** technology
- **120k successful cases** and a growing sales pipeline
- **Clear vision of** profitability
- Strong IP with patents and **regulatory approvals**

Strong pedigree

- **Global leader** in regenerative medicine
- **Leading-edge** bioresorbable and biomimetic implants
- Renowned for many **world-first surgeries**

Breakthrough technology

- **Novel implants** which empower in-situ natural bone regeneration
- Our implants **dissolve over time** with no permanent residue

Superior outcomes

- **Superior treatment** in comparison to metal and plastic implants
- Delivering **patient quality of life** with a low risk of infection

Why Osteopore?

Global opportunity

- Technology platform with **potential lateral expansion into regenerative medicine**
- Projected **USD $532b** regenerative medicine market at a **CAGR of 32%** (2024-2033) [1]

Addressable market

- **4 business units** targeting a total addressable market of **~USD $50b**
- **High-impact collaborations** to boost innovation

Market approvals

- **Key regulatory approvals** in Tier 1 markets including the US and the EU
- Products sold in 25+ countries across **APAC, ASEAN, EMEA, LATAM & North America**

Blue sky

- Potential **expansion into new markets** such as tendon augmentation
- Developing possible **surgical applications for the veterinary market**

1 Allied Market Research - https://www.alliedmarketresearch.com/regenerative-medicines-market

OSTEOPORE.COM

Investment highlights

1#
De-risked Profile

Globally validated technology, 120K successful cases, growing sales and a clear profit vision

2#
Breakthrough Technology

Strong IP with patented implants and regulatory approvals, empowering natural bone regeneration

3#
Strong Pedigree & Outcomes

Global leader in regenerative medicine recognised for its world-first surgeries and patient outcomes

4#
Global Market Opportunity

Significant market potential as the new standard of care globally with Tier 1 regulatory approvals

Osteopore®

Mark Leong
Executive Chairman
E: mark_leong@osteopore.com

Lim Yujing
Chief Executive Officer & Chief Technology Officer
E: lim_yujing@osteopore.com

Isaac Stewart
Investor & Media Relations
E: istewart@purple.au